France Épargne

France Épargne Corporate

IP and royalty financing for companies

France Épargne Corporate connects companies seeking to finance €20m or more with the private debt funds whose ticket size, instruments and sectors match their case. Transactions on pharmaceutical royalties reached an estimated $10.0bn in 2025.

Royalty financing in 2025

$10.0bn
of transactions on pharmaceutical royalties in 2025 (estimate)
21
pharmaceutical royalty transactions of $500m or more since 2020 (count as of February 2026)
$1.765bn
notes that Concord issued in July 2025 against more than 1.3 million copyrights of its music catalogue

Transactions

Financings on intellectual property assets

  1. Synthetic royalty

    The company that develops or markets a product grants the funder a percentage of its future sales of that product in exchange for funding. The funder pays the money in tranches. Each tranche depends on clinical results, marketing approval or sales.

  2. Sale of an existing royalty

    A licensor receives a percentage of the sales made by its licensee. It sells all or part of these future flows for an upfront payment.

  3. Secured term loan

    The lender grants a senior secured loan alongside the royalty. The tranches become available after marketing approval and when sales thresholds are reached.

    Growth financing
  4. Music catalogue securitisation

    The issuer places rated notes secured by the copyrights of a catalogue. The Concord notes issued in July 2025 have terms of 5, 7 and 10 years.

  5. Pledge over patents and trademarks

    The lender takes a pledge over the borrower’s patents or trademarks. It registers the pledge in the National Patent Register or the National Trademark Register. It then enforces the pledge against third parties.

  6. Pledge over software

    The pledge covers the exploitation right of the software. The lender registers the pledge in a special register of the INPI. It describes the scope of the security there. The source code is part of this scope.

Market

Transactions and security on intellectual property

Three financings backed by royalties and rights in 2025
TransactionUnderlyingAmountTerms
Revolution Medicines, synthetic royalty (June 2025)Worldwide sales of daraxonrasib, a pancreatic cancer drugUp to $1,250mFive tranches of $250m, the first two mandatory, the next three at the borrower’s option
Revolution Medicines, secured term loan (June 2025)Senior secured loan, tranches tied to approval and salesUp to $750mSOFR plus 5.75%, SOFR floor of 3.5%, maturity six years after the first drawdown
Concord, securitisation (July 2025)Catalogue of more than 1.3 million copyrights valued at more than $5.1bn$1,765mSenior notes of 5, 7 and 10 years rated A+ (KBRA) and A2 (Moody’s)

SOFR (Secured Overnight Financing Rate) is the overnight reference rate of the US dollar. Revolution Medicines draws the first tranche of the term loan after the FDA (Food and Drug Administration) approves daraxonrasib.

Rates of the Revolution Medicines synthetic royalty by annual sales of daraxonrasib
TrancheUp to $2bn$2bn to $4bn$4bn to $8bn
Tranche 12.55%1.50%0.60%
Tranche 22.00%1.00%0.40%
Tranche 31.50%0.80%0.40%
Tranche 41.00%0.75%0.50%
Tranche 50.75%0.50%0.50%
Total7.80%4.55%2.40%

Rates are adjusted pro rata to the amount drawn on each tranche.

Pledges over intellectual property rights in France
RightForm of the deedEnforceability against third parties
PatentIn writing, on pain of nullity, for transfer and licenceRegistration in the National Patent Register
TrademarkIn writing, on pain of nullity, for transfer and pledgeRegistration in the National Trademark Register
SoftwareIn writing, on pain of nullityRegistration in the special register of the INPI, valid five years, renewable

Questions

Frequently asked questions

What is a synthetic royalty?
A synthetic royalty is a contractual right to a percentage of a product’s sales, created for the funder in exchange for funding. In June 2025, Revolution Medicines obtained up to $1.25bn against a royalty on worldwide sales of daraxonrasib. The combined rate reaches 7.80% up to $2bn of annual sales, 4.55% from $2bn to $4bn and 2.40% from $4bn to $8bn, pro rata to the tranches drawn.
How is a patent or a trademark pledged in France?
The French Intellectual Property Code requires a written deed, on pain of nullity, for the transfer or the pledge of a trademark. Deeds that transfer or modify the rights attached to a patent become enforceable against third parties once registered in the National Patent Register kept by the INPI. Deeds on a trademark follow the same rule with the National Trademark Register. A third party that knew of the deed before acquiring its rights remains bound by it without registration.
How is software pledged?
Article L132-34 of the French Intellectual Property Code allows a pledge over the exploitation right of software. The parties put the agreement in writing. Without a written deed, the agreement is void. The creditor registers the pledge in a special register kept by the INPI. Without registration, the creditor cannot enforce it against third parties. The creditor describes the scope of the security there. The source code is part of this scope. Ranking follows the order of registration and a registration lapses after five years unless renewed.
How large is the pharmaceutical royalty market?
Transactions on pharmaceutical royalties reached an estimated $10.0bn in 2025. From 2020 to February 2026, 21 transactions each exceeded $500m. With a royalty sale, a biotech company keeps operational control of its programmes. It retains a larger share of their economic value than in a partnership with a large pharmaceutical group. The funding reduces the administrative work of such a partnership.
How does a music catalogue securitisation work?
Concord issued $1.765bn of senior notes in July 2025. A catalogue of more than 1.3 million copyrights, valued at more than $5.1bn, secures these notes. Their terms are 5, 7 and 10 years. KBRA rates the notes A+. Moody’s rates them A2. The proceeds repay the $1.65bn notes issued in 2022. It is the fourth securitisation of Concord.
From what amount can a company request an introduction for intellectual property financing?
France Épargne Corporate introduces companies whose financing need reaches €20m or more to private debt funds and other non bank lenders. The total amount requested against patents, trademarks or royalties must reach this threshold. The lender alone decides to lend. It sets the amount, the tranches, the rate and the security.

Contact

Request an introduction to lenders